Short answer
Nurix Therapeutics, Inc. (NRIX) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 8.01 (Other Events). Sanofi discontinued the Phase 1 trial and terminated SAR448272, an oral STAT6 degrader.
Nurix Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Sanofi discontinued the Phase 1 trial and terminated SAR448272, an oral STAT6 degrader
- Nurix loses eligibility for future development, regulatory and commercial milestones and royalties tied to SAR448272
- Remaining Sanofi collaboration programs retain potential milestone and royalty value
- Sanofi retains discretion over advancing other licensed programs, leaving broader partnership economics uncertain
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nurix Therapeutics, Inc. 8-K filings
Get the next NRIX 8-K as it lands
Follow NRIX for push alerts, or ask the research agent what this filing means.